Revenue: As of FY2025, the actual value is USD 5.199 M.EPS: As of FY2025, the actual value is USD -0.86.EBIT: As of FY2025, the actual value is USD -5.288 M.<h4>Total Revenues</h4>Zeo ScientifiX, Inc. reported total revenues of $5,199,000 for the fiscal year ended October 31, 2025, an increase of 12.5% from $4,620,000 in the prior year. <h4>Segment Revenue</h4><ul><li>Higher Concentration Allogenic Aesthetic Biologics: Revenue decreased to $2,171,000 (41.8% of total revenue) in FY2025 from $2,420,000 (52.4% of total revenue) in FY2024, representing a -5.4% change in revenue and a -33.1% decrease in units sold. </li><li>Lower Concentration Allogenic Aesthetic Biologics: Revenue increased to $1,394,000 (26.8% of total revenue) in FY2025 from $1,363,000 (29.5% of total revenue) in FY2024, reflecting a 0.7% increase in revenue and a 34.2% increase in units sold. </li><li>Total Allogenic Aesthetic Biologics: Combined revenue for these categories was $3,565,000 (68.6% of total revenue) in FY2025, down from $3,783,000 (81.9% of total revenue) in FY2024. </li><li>PPX™ Service Platform: Revenue significantly increased to $1,527,000 (29.4% of total revenue) in FY2025 from $614,000 (13.3% of total revenue) in FY2024, marking a 19.8% increase. </li><li>Other: Revenue decreased to $107,000 (2.0% of total revenue) in FY2025 from $223,000 (4.8% of total revenue) in FY2024, a -2.5% change. </li></ul><h4>Operational Metrics</h4><ul><li>Cost of Revenues: Increased by 10.3% to $931,000 in FY2025 from $844,000 in FY2024, primarily due to a $157,000 increase in PPX™ service platform costs, partially offset by a $70,000 decrease in allogenic aesthetic biologic product costs. </li><li>Gross Profit: Rose by 13.0% to $4,268,000 (82.0% of revenues) in FY2025 from $3,776,000 (81.7% of revenues) in FY2024. </li><li>General and Administrative Expenses: Increased by 6.1% to $9,654,000 in FY2025 from $9,095,000 in FY2024, driven by higher stock-based compensation, laboratory costs, and professional fees, partially offset by reduced commissions, travel, marketing, administrative, and research and development costs. </li><li>Net Loss: Increased to - $5,521,000 in FY2025 from - $4,705,000 in FY2024. </li><li>Other Income (Expense): Other income decreased to $101,000 in FY2025 from $751,000 in FY2024, mainly due to non-recurring income in FY2024, including a - $221,000 write-off of advances, - $168,000 from settlement of the Amended Skincare Agreement, and - $89,000 from insurance claims. Other expense increased to $236,000 in FY2025 from $137,000 in FY2024, primarily due to increased interest costs and inducement expenses to convert Notes. </li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: Decreased to - $718,000 in FY2025 from - $1,450,000 in FY2024, representing a $732,000 decrease in cash used, attributed to increased gross profit and changes in operating assets and liabilities. </li><li>Net Cash Used in Investing Activities: Decreased to - $23,000 in FY2025 from - $45,000 in FY2024, mainly due to a decrease in investments in non-marketable securities. </li><li>Net Cash Provided by Financing Activities: Decreased to $305,000 in FY2025 from $396,000 in FY2024, due to lower proceeds from equity sales and higher finance lease payments, partially offset by warrant exercise proceeds. </li><li>Cash, End of Year: Decreased to $221,000 in FY2025 from $657,000 in FY2024. </li></ul><h4>Outlook / Guidance</h4>Zeo ScientifiX, Inc. anticipates continued dependence on additional investment capital to fund ongoing operating expenses and research and development costs for new products and clinical studies. The company expects its current market capitalization and common stock liquidity to hinder its ability to raise equity proceeds, making future funding costly and potentially dilutive. There is substantial doubt about the company’s ability to continue as a going concern for the next 12 months due to net losses, cash used in operations, and a working capital deficit.

Zeo ScientifiX, Inc. | 10-K: FY2025 Revenue: USD 5.199 M